Trial Profile
Phase II Study Designed To Evaluate Safety and Tumor Debulking Mechanism of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs T-cell vaccine AlloVax (Primary) ; T-cell vaccine-AlloStim
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors Immunovative Therapies
- 21 Jan 2020 Status changed from active, no longer recruiting to completed.
- 07 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
- 07 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.